Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101222 | 0.93 | GHSR (0.86) | GHSR | |
| SCHEMBL4101225 | 0.93 | GHSR (0.86) | GHSR | |
| SCHEMBL4113448 | 0.90 | GHSR (0.87) | GHSR | |
| SCHEMBL743442 | 0.89 | GHSR (0.81) | GHSR | |
| SCHEMBL4108043 | 0.89 | GHSR (0.81) | GHSR | |
| SCHEMBL4101942 | 0.87 | GHSR (0.87) | GHSR | |
| SCHEMBL4115683 | 0.86 | GHSR (0.88) | GHSR | |
| SCHEMBL4108147 | 0.85 | GHSR (0.82) | GHSR | |
| SCHEMBL4108143 | 0.85 | GHSR (0.82) | GHSR | |
| SCHEMBL3432562 | 0.83 | GHSR (0.81) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546435-B2 | Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors | AETERNA ZENTARIS GMBH (DE) | 2013-10-01 | — | — | US | claimed |
| EP-2616070-A1 | NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | Æterna Zentaris GmbH (DE) | 2013-07-24 | — | — | EP | claimed |
| US-20120083494-A1 | NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2012-04-05 | — | — | US | claimed |
| WO-2012035124-A1 | NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | ÆTERNA ZENTARIS GMBH (DE) | 2012-03-22 | — | — | WO | claimed |
| EP-2431035-A1 | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors | Æterna Zentaris GmbH (DE) | 2012-03-21 | — | — | EP | claimed |
| US-8546435-B2 | Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors | AETERNA ZENTARIS GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546435-B2 | Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors | AETERNA ZENTARIS GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546435-B2 | Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors | AETERNA ZENTARIS GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| EP-2616070-A1 | NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | Æterna Zentaris GmbH (DE) | 2013-07-24 | — | — | EP | disclosed |
| US-20120083494-A1 | NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083494-A1 | NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083494-A1 | NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2012-04-05 | — | — | US | disclosed |
| WO-2012035124-A1 | NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | ÆTERNA ZENTARIS GMBH (DE) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012035124-A1 | NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | ÆTERNA ZENTARIS GMBH (DE) | 2012-03-22 | — | — | WO | disclosed |
| EP-2431035-A1 | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors | Æterna Zentaris GmbH (DE) | 2012-03-21 | — | — | EP | disclosed |
| EP-2431035-A1 | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors | Æterna Zentaris GmbH (DE) | 2012-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083494-A1 | NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | GPR119, GIPR, GHSR | GHSR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.